Capital/Biotech & Pharma

Deploy a Chief Financial Officer for your biotech or pharma company.

Bypass bloated consulting firms. Secure a US-based, Ivy League-educated CFO to navigate crossover or series c fundraise — entirely remotely, deployed in 48 hours.

48 hr
Avg. Deployment
100%
US-Based · Ivy League
14 day
No-Cause Cancellation
The Mandate

What Biotech & Pharma CEOs hire CFOs to solve.

  • 01Capital efficiency between trial milestones
  • 02Clinical, regulatory and commercial coordination
  • 03BD, licensing and pharma-partner negotiations
  • 04GxP, quality and supply chain readiness
Common Engagements

Where this CFO plugs in across Biotech & Pharma.

Crossover or Series C fundraise

Pre-audit cleanup ahead of Series B due diligence

BD and licensing program

Cash flow crisis stabilization in 60 days

Commercial launch preparation

M&A buy-side or sell-side preparation

Quality and compliance overhaul

Transition from cash to accrual GAAP reporting

Ready to DeployYour operator can be on the inside by Thursday.Choose a Tier
Deliverables

What lands in week one.

  • Three-statement model with scenario and sensitivity analysis
  • 13-week rolling cash flow and treasury dashboard
  • Board-ready monthly financial package
  • Audit-ready chart of accounts and revenue recognition policy
KPIs Owned

The scoreboard they answer to.

  • ·Days cash on hand and burn multiple
  • ·Forecast accuracy variance (<5%)
  • ·Close cycle time (target: 10 business days)
  • ·Audit findings and material weaknesses (target: zero)

A Crimson Bench CFO gives management, investors, lenders, and auditors a finance function that can withstand diligence: clean numbers, clear cash visibility, and capital decisions tied to operating reality.

Still Evaluating?

Start with a $1,500 Executive Diagnostic — 2 hours, 3-page roadmap, refundable.

Live Bench